Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer

Overview of attention for article published in Journal of Clinical Oncology, June 2024

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 3 X users

facebook: 1 Facebook page

Readers on

mendeley: 19 Mendeley

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 7,236 followers.

https://t.co/1cQHV1glVY

https://t.co/GPltTBUoPa

Un año de everolimus más terapia endocrina adyuvante no mejora resultados en pac c/CA mama de alto riesgo, aunque los inhibidores mTOR podrían funcionar en las pacientes que persisten premenopáusicas luego de la quimioterapia #everolimus #breastcancer htt…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.